대웅제약

069620KOSPI의약품 제조업

56.4 / 100

Reference Date: 2026-06-10

Financial Score24.5 / 40

News Sentiment17.9 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Plunged 18.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Daewon Pharmaceutical, established in 2002, is a leading pharmaceutical company specializing in the production and sales of specialty drugs and high-purity botulinum toxin 'Nabohta'. In 2025, it achieved sales of 13.91 trillion KRW and operating profit of 2.04 trillion KRW, driven by global market expansion, AI-based digital healthcare solutions, and R&D investments in innovative drugs.

Number of Employees

1,794people

Average Salary

77.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.11Industry Average 11.936.5Point

Lower than industry avg (good)

PBR

1.21Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

18.71Industry Average 4.017.0Point

4.7x industry avg (excellent)

Debt Ratio

56.35Industry Average 12.430.0Point

4.5x industry avg (risky)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.8% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 11.9% (improving, 3yr)

Detailed News Sentiment

66 totalPositive 41Neutral 21Negative 4Average Sentiment Score 71.4

Positive
"전문성 강화·공중보건 증진"…대웅-인니 약사회 '맞손'
대웅제약과 인도네시아 약사회 간의 협력 강화 협약으로 전문성 향상과 공중보건 증진이 기대되어 긍정적 영향 예상.
Positive
대웅제약, 인니 약사회와 MOU…"2030년 일반의약품 1위 목표"
대웅제약이 인도네시아 약사회와 협력하여 약사 교육 및 전문성 강화를 통해 글로벌 시장 진출을 가속화하고 있다.
Positive
대웅제약, 엔블로 혈당 강하 통합 모델 유럽 학회서 발표
대웅제약의 엔블로 혈당 관리 통합 모델 연구 결과가 유럽 학회에서 발표되어 긍정적인 시장 반응을 기대할 수 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 118,300Won52-week high 194,00052-week low 118,300

1-month return0.0Point

1m -18.30% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral투자판단관련주요경영사항 (엔블로젬(Envlozem)의 국내 품목허가 신청)2026-05-26
Neutral투자판단관련주요경영사항 (엔블로정(Envlo) 0.3mg 멕시코 품목허가 승인)2026-05-26
Neutral투자판단관련주요경영사항 (비만치료용 세마글루타이드(4주 장기지속형 주사제) 기술도입 계약 체결)2026-05-21
Neutral[기재정정]투자판단관련주요경영사항 (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)2026-05-20